Lytix Biopharma Q1 2025: Progress in NeoLIPA but Financial Weakness for Verrica - Redeye

Redeye comments on Lytix Biopharma’s first quarter review of 2025. The NeoLIPA study is progressing with a planned interim readout in Q3 2025. Despite the successful share issue in November 2024, Verrica currently does not have funding for the rest of 2025, which we discuss.

Länk till analysen i sin helhet: https://www.redeye.se/research/1109643/lytix-biopharma-q1-2025-progress-in-neolipa-but-financial-weakness-for-verrica?utm_source=finwire&utm_medium=RSS